Tuesday, September 20, 2016 11:41:43 AM
GLTA
HCIT
LINK: https://bif16.eventsbio.com/connect/search.ww
OncoSec Medical Incorporated OncoSec is pioneering new technologies to stimulate the body’s immune system to target and attack cancer. Our mission is to deliver safer and more effective cancer treatments that can provide long-term benefits for patients through our proprietary technology. OncoSec's core immunotherapy platform, ImmunoPulse, is designed to deliver DNA-based therapeutics directly into tumors and reverse the immuno-suppressive tumor microenvironment. Our lead program, ImmunoPulse IL-12, employs this intratumoral technology to enhance the local expression of interleukin-12 (IL-12). ImmunoPulse IL-12 is currently in clinical development for several indications including metastatic melanoma and triple-negative breast cancer. This includes our Phase II combination trial of ImmunoPulse IL-12 and Merck’s anti-PD-1 drug KEYTRUDA in patients with metastatic melanoma. The program’s current focus is on the significant unmet medical need in refractory and non-responders to anti-PD-1/PD-L1 therapies in melanoma. In Phase I and II clinical trials, ImmunoPulse IL-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors and has shown the potential to reach beyond the site of local treatment to initiate a systemic immune response. In addition to ImmunoPulse IL-12, OncoSec is also identifying and developing new immune-targeting agents for use with the ImmunoPulse platform.
View Less
Company Presentation
Punit Dhillon
Scheduling Options
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM